Complete Switch to Everolimus in Long-Term Kidney Transplants: Evolution of the Renal Function

Transplantation Proceedings

Volumn 41, Issue 6, 2009, Pages 2345-2347

  Fernandez A ^a   Marcen R ^a   Galeano, C ^a   Caldes S ^a   Amezquita, Y ^a   Villafruela, J ^a   Pascual, J ^a   Burgos, J ^a   Rodriguez Mendiola N ^a   Ortuno J ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MALE; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR; VERRUCA VULGARIS;

ADULT; AGED; CADAVER; CALCINEURIN; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CREATININE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 68949200871     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.06.162     Document Type: Article

References (12)

1. Chapman J.R., O'Connell P.J., and Nankivell B.J. Chronic renal allograft dysfunction. J Am Soc Nephrol 16 (2005) 3015
2. Chapman J.R., Valantine H., Albanell J., et al. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc 39 (2007) 2937
3. Pascual J. Calcineurin inhibitors minimisation and anti-proliferative strategies. Nephrol Ther 4 suppl 1 (2008) S29
4. de Fijter J.W. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation. Nephrol Dial Transplant 22 suppl 1 (2007) 123
5. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 20 (2005) 2517
6. Ruiz J.C., Sánchez A., Rengel M., et al. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. Transplant Proc 39 (2007) 2157
7. Sánchez Fructuoso A., Ruiz San Millán J.C., Calvo N., et al. Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an Everolimus-based therapy in maintenance renal transplant patients. Transplant Proc 39 (2007) 2148
8. Nankivell B.J., Borrows R.J., Fung C.L., et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78 (2004) 557
9. Fernández A., Marcén R., Pascual J., et al. Conversion from calcineurin inhibitors to Everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 38 (2006) 2453
10. Marcén R., Pascual J., Tato A.M., et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 35 (2003) 1714
11. Mathew T., Kreis H., and Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 18 (2004) 446
12. Lutz J., Zou H., Liu S., et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 76 (2003) 508